Protocol Ledger

NCT07076706 · Phase II · COMPLETED

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

Interventional Phase II clinical trial protocol NCT07076706 sponsored by Beijing Dayspring Pharmaceutical Technology Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-05 Enrollment: 110 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07076706
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07076706
Protocol FieldVerified Registry Value
NCT IdentifierNCT07076706
Consolidated Lead SponsorBeijing Dayspring Pharmaceutical Technology Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment110 participants (ACTUAL)
Registered Start Date2024-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI